Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | HBB | P68871 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.30 |
| ▸ | BACE1 | P56817 | 1/20 | 0.30 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4750893 | 0.67 | ALDH1A1 (0.32) | ALDH1A1LMNATP53HPGDALOX15 | |
| SCHEMBL15045875 | 0.66 | STING1 (0.42) | ALDH1A1LMNATP53HPGDALOX15 | |
| SCHEMBL14001854 | 0.65 | STING1 (0.41) | STING1 | |
| SCHEMBL16203318 | 0.64 | GSK3B (0.31) | GSK3BBACE1 | |
| SCHEMBL12958962 | 0.64 | — | — | |
| SCHEMBL18870640 | 0.63 | STING1 (0.36) | STING1 | |
| SCHEMBL14076163 | 0.63 | BACE1 (0.44) | BACE1 | |
| SCHEMBL17928575 | 0.61 | STING1 (0.32) | STING1 | |
| SCHEMBL14818148 | 0.61 | — | — | |
| SCHEMBL15257768 | 0.61 | PDE2A (0.44) | STING1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3543238-A1 | NUCLEOSIDE DERIVATIVE HAVING PHYSICAL ACTIVITIES INCLUDING ANTI-VIRAL ACTIVITY | National Center for Global Health and Medicine (JP) | 2019-09-25 | — | — | EP | disclosed |
| US-10196344-B2 | Glaucocalyxin a derivative and preparation method and application thereof | SUZHOU PHARMAVAN CANCER RESEARCH CENTER CO., LTD. (CN) | 2019-02-05 | — | — | US | disclosed |
| WO-2016138461-A1 | WATER SOLUBLE FLUORESCENT OR COLORED DYES COMPRISING CONJUGATING GROUPS | SONY CORPORATION (JP) | 2016-09-01 | — | — | WO | disclosed |
| US-8287939-B2 | Method for manufacturing substrate for biochip | AZBIL CORPORATION (JP) | 2012-10-16 | — | — | US | disclosed |
| US-20120122819-A1 | GUANINE RIBOSWITCH BINDING COMPOUNDS AND THEIR USE AS ANTIBIOTICS | SOCPRA - SCIENCES ET GENIE S.E.C. (CA) | 2012-05-17 | — | — | US | disclosed |
| US-20120122819-A1 | GUANINE RIBOSWITCH BINDING COMPOUNDS AND THEIR USE AS ANTIBIOTICS | SOCPRA - SCIENCES ET GENIE S.E.C. (CA) | 2012-05-17 | — | — | US | disclosed |
| US-20100288727-A1 | METHOD FOR MANUFACTURING SUBSTRATE FOR BIOCHIP | YAMATAKE CORPORATION (JP) | 2010-11-18 | — | — | US | disclosed |
| US-7807105-B2 | Substrate for biochip | YAMATAKE CORPORATION (JP) | 2010-10-05 | — | — | US | disclosed |
| US-20080253928-A1 | Substrate surface capable of reacting with biological substances and having a region not reacting with the biological substances;sunken bottomed wells formed in the surface; and a layer capable of reacting with the biological substances having a surface exposed only at the bottoms of the bottomed wells | YAMATAKE CORPORATION (JP) | 2008-10-16 | — | — | US | disclosed |
| EP-1939621-A1 | SUBSTRATE FOR BIOCHIP, BIOCHIP, METHOD FOR MANUFACTURING SUBSTRATE FOR BIOCHIP, AND METHOD FOR MANUFACTURING BIOCHIP | Yamatake Corporation (JP) | 2008-07-02 | — | — | EP | disclosed |
| US-20070135436-A1 | Chemical compounds | CLAVIS PHARMA AS (NO) | 2007-06-14 | — | — | US | disclosed |
| US-20070135436-A1 | Chemical compounds | CLAVIS PHARMA AS (NO) | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10196344-B2 | Glaucocalyxin a derivative and preparation method and application thereof | SSB, GYPA, PEX14 | ALDH1A1 4846/4885LMNA 199/4885TP53 2023/4885 |
| US-20070135436-A1 | Chemical compounds | FASN, ALOX5, ALOX15 | ALDH1A1 88/4885LMNA 201/4885TP53 1838/4885 |
| US-20120122819-A1 | GUANINE RIBOSWITCH BINDING COMPOUNDS AND THEIR USE AS ANTIBIOTICS | GDA, RNMT, GNPDA1 | ALDH1A1 1272/4885LMNA 3267/4885TP53 1184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.